AbGenomics lead drug applicant AbGn-168H.

We are delighted to have the continuing support of our traders. This round of funding will provide AbGenomics additional capital to continue its clinical-stage programs through proof of concept for addressing major unmet requirements in autoimmune diseases and GI cancers. stated Dr. Rong-Hwa Lin, Founder and CEO of AbGenomics.. AbGenomics raises $11 million in current financing round AbGenomics International announced today that it all offers raised $11 million in current financing circular. AbGenomics use the proceeds to keep advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics’ lead drug applicant AbGn-168H, a humanized monoclonal antibody that induces loss of life of pathogenic activated T cells for the treatment of autoimmune illnesses, will enter Stage II scientific trials in 3Q, 2012.Hausman, PhD David G. Hunter, MD, PhD Tag E. Ireland, PhD Carolyn M. Kalsow, PhD J. Daniel Nelson, MD Maureen K. Powers, PhD John C. Saari, PhD Steven D. Schwartz, MD Marvin L. Sears, MD Arun D. Singh, MD Einar Stefansson, MD Frank Thorn, OD, PhD Joyce Tombran-Tink, PhD David R. Whikehart, PhD.

Lisa Rosenbaum, M.D.: Transitional Enduring or Chaos Damage? The EHR and the Disruption of Medicine A decade ago, a primary care physician We admired appeared to come undone. His efficiency had derived not really from rushing between individuals but from knowing them so well that his charting was effortless and fast.